Development
Takeda Pharmaceutical Company Limited
TAK
$15.31
-$0.215-1.39%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 315.43% | -151.04% | 176.76% | -72.15% | 89.02% |
| Total Depreciation and Amortization | 0.21% | 1.21% | 21.68% | -18.15% | 3.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 486.15% | -109.47% | 214.29% | -245.61% | 262.25% |
| Change in Net Operating Assets | -334.71% | 130.09% | -246.93% | 197.88% | 398.02% |
| Cash from Operations | -27.94% | 104.51% | -69.68% | -17.24% | 67.67% |
| Capital Expenditure | -21.75% | 21.76% | -23.84% | -13.91% | -11.90% |
| Sale of Property, Plant, and Equipment | -96.86% | 71,853.93% | -98.80% | 5,628.44% | -126.44% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 100.00% | -101.79% | -95.49% | -- | -- |
| Other Investing Activities | 10.31% | 86.65% | 48.25% | -3,220.95% | -737.71% |
| Cash from Investing | -21.60% | 78.41% | 41.41% | -900.92% | -68.12% |
| Total Debt Issued | -- | -100.00% | 82.61% | -- | -- |
| Total Debt Repaid | 38.56% | -41.97% | -28.68% | 67.70% | -2,372.36% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1,392.64% | 93.41% | -1,109.55% | 91.39% | -1,034.94% |
| Other Financing Activities | -229.52% | 205.85% | 4.50% | 36.62% | -32.66% |
| Cash from Financing | 31.98% | -131.28% | -743.80% | 98.38% | -721.39% |
| Foreign Exchange rate Adjustments | -176.22% | -74.25% | 6,810.20% | 97.64% | -191.69% |
| Miscellaneous Cash Flow Adjustments | -- | 100.00% | -- | -- | -- |
| Net Change in Cash | -1,839.01% | 100.73% | -38.05% | -43.00% | -172.76% |